Literature DB >> 12414935

Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions.

Christine Krempl1, Brian R Murphy, Peter L Collins.   

Abstract

The genome of human respiratory syncytial virus (RSV) encodes 10 mRNAs and 11 proteins in the order 3'-NS1-NS2-N-P-M-SH-G-F-M2-1/M2-2-L-5'. The G and F glycoproteins are the major RSV neutralization and protective antigens. It seems likely that a high level of expression of G and F would be desirable for a live RSV vaccine. For mononegaviruses, the gene order is a major factor controlling the level of mRNA and protein expression due to the polar gradient of sequential transcription. In order to increase the expression of G and F, recombinant RSVs based on strain A2 were constructed in which the G or F gene was shifted from the sixth or seventh position (in a genome lacking the SH gene), respectively, to the first position (rRSV-G1/DeltaSH and rRSV-F1/DeltaSH, respectively). Another virus was made in which G and F were shifted together to the first and second positions, respectively (rRSV-G1F2/DeltaSH). Shifting one or two genes to the promoter-proximal position resulted in increased mRNA and protein expression of the shifted genes, with G and F expression increased up to 2.4-and 7.8-fold, respectively, at the mRNA level and approximately 2.5-fold at the protein level, compared to the parental virus. Interestingly, the transcription of downstream genes was not greatly affected even though shifting G or F, or G and F together, had the consequence of moving the block of genes NS1-NS2-N-P-M-(G) one or two positions further from the promoter. The efficiency of replication of the gene shift viruses in vitro was increased up to 10-fold. However, their efficiency of replication in the lower respiratory tracts of mice was statistically indistinguishable from that of the parental virus. In the upper respiratory tract, replication was slightly reduced on some days for viruses in which G was in the first position. The magnitude of the G-specific antibody response to the gene shift viruses was similar to that to the parental virus, whereas the F-specific response was increased up to fourfold, although this was not reflected in an increase of the neutralizing activity. Thus, shifting the G and F genes to the promoter-proximal position increased virus replication in vitro, had little effect on replication in the mouse, and increased the antigen-specific immunogenicity of the virus beyond that of parental RSV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12414935      PMCID: PMC136893          DOI: 10.1128/jvi.76.23.11931-11942.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response.

Authors:  E B Flanagan; L A Ball; G W Wertz
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Transcription of human respiratory syncytial virus genome RNA in vitro: requirement of cellular factor(s).

Authors:  S Barik
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  Bronchiolitis-associated hospitalizations among US children, 1980-1996.

Authors:  D K Shay; R C Holman; R D Newman; L L Liu; J W Stout; L J Anderson
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

4.  Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells.

Authors:  L S Wyatt; B Moss; S Rozenblatt
Journal:  Virology       Date:  1995-06-20       Impact factor: 3.616

5.  Functional cDNA clones of the human respiratory syncytial (RS) virus N, P, and L proteins support replication of RS virus genomic RNA analogs and define minimal trans-acting requirements for RNA replication.

Authors:  Q Yu; R W Hardy; G W Wertz
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

6.  Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.

Authors:  B R Murphy; A V Sotnikov; L A Lawrence; S M Banks; G A Prince
Journal:  Vaccine       Date:  1990-10       Impact factor: 3.641

7.  Sendai virus gene expression in lytically and persistently infected cells.

Authors:  H E Homann; P H Hofschneider; W J Neubert
Journal:  Virology       Date:  1990-07       Impact factor: 3.616

8.  Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.

Authors:  M Connors; A B Kulkarni; P L Collins; C Y Firestone; K L Holmes; H C Morse; B R Murphy
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

9.  RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA.

Authors:  H Grosfeld; M G Hill; P L Collins
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.

Authors:  M Connors; P L Collins; C Y Firestone; B R Murphy
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more
  17 in total

1.  Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats.

Authors:  Jinying Ge; Xijun Wang; Lihong Tao; Zhiyuan Wen; Na Feng; Songtao Yang; Xianzhu Xia; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.

Authors:  Peter L Collins; Brian R Murphy
Journal:  Proc Am Thorac Soc       Date:  2005

3.  Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus.

Authors:  Bo Chi; Harold L Dickensheets; Kirsten M Spann; Marc A Alston; Cindy Luongo; Laure Dumoutier; Jiaying Huang; Jean-Christophe Renauld; Sergei V Kotenko; Mario Roederer; Judy A Beeler; Raymond P Donnelly; Peter L Collins; Ronald L Rabin
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 4.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

5.  Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.

Authors:  Benson Yee Hin Cheng; Emilio Ortiz-Riaño; Juan Carlos de la Torre; Luis Martínez-Sobrido
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

6.  The aberrant gene-end transcription signal of the matrix M gene of human parainfluenza virus type 3 downregulates fusion F protein expression and the F-specific antibody response in vivo.

Authors:  Matthias Lingemann; Sonja Surman; Emérito Amaro-Carambot; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

7.  Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression.

Authors:  Emily Julik; Jorge Reyes-Del Valle
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

Review 8.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Quantitative proteomic analysis of A549 cells infected with human respiratory syncytial virus.

Authors:  Diane C Munday; Edward Emmott; Rebecca Surtees; Charles-Hugues Lardeau; Weining Wu; W Paul Duprex; Brian K Dove; John N Barr; Julian A Hiscox
Journal:  Mol Cell Proteomics       Date:  2010-07-20       Impact factor: 5.911

10.  Live-attenuated respiratory syncytial virus vaccines.

Authors:  Ruth A Karron; Ursula J Buchholz; Peter L Collins
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.